332 related articles for article (PubMed ID: 30623616)
41. Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: A PRISMA-compliant systematic review and meta-analysis.
Zhang H; Chen L; Wu L; Huang J; Li H; Wang X; Weng H
Medicine (Baltimore); 2020 Apr; 99(16):e19493. PubMed ID: 32311922
[TBL] [Abstract][Full Text] [Related]
42. Serum KL-6 in fibrotic NSIP: Correlations with physiologic and radiologic parameters.
Sakamoto K; Taniguchi H; Kondoh Y; Johkoh T; Sumikawa H; Kimura T; Nishiyama O; Kato K; Kataoka K; Ono K; Kitaichi M; Hasegawa Y
Respir Med; 2010 Jan; 104(1):127-33. PubMed ID: 19811899
[TBL] [Abstract][Full Text] [Related]
43. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
Chen F; Lu X; Shu X; Peng Q; Tian X; Wang G
Intern Med J; 2015 Jun; 45(6):641-7. PubMed ID: 25827843
[TBL] [Abstract][Full Text] [Related]
44. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review.
d'Alessandro M; Bergantini L; Cameli P; Vietri L; Lanzarone N; Alonzi V; Pieroni M; M Refini R; Sestini P; Bonella F; Bargagli E
Biomark Med; 2020 Jun; 14(8):665-674. PubMed ID: 32613855
[No Abstract] [Full Text] [Related]
45. Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features.
Xue M; Cai C; Zeng Y; Xu Y; Chen H; Hu H; Zhou L; Sun B
Medicine (Baltimore); 2021 Jan; 100(4):e24260. PubMed ID: 33530214
[TBL] [Abstract][Full Text] [Related]
46. Potential of Krebs von den Lungen-6 as a predictor of relapse in interstitial pneumonia with anti-aminoacyl tRNA synthetase antibodies-positive dermatomyositis.
Isoda K; Kotani T; Takeuchi T; Konma J; Ishida T; Hata K; Otani K; Fujiwara H; Shoda T; Makino S; Arawaka S
Clin Respir J; 2018 Jul; 12(7):2235-2241. PubMed ID: 29633527
[TBL] [Abstract][Full Text] [Related]
47. Krebs von den Lungen-6, a promising marker in evaluating the severity of interstitial lung disease in Egyptian rheumatoid arthritis patients.
Hammoda RM; Salah-ElDin H; El-Gharbawy NH; Ragab D
Egypt J Immunol; 2021 Oct; 28(4):241-249. PubMed ID: 34882373
[TBL] [Abstract][Full Text] [Related]
48. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
Nakamura K; Kato M; Shukuya T; Mori K; Sekimoto Y; Ihara H; Kanemaru R; Ko R; Shibayama R; Tajima K; Koyama R; Shimada N; Nagashima O; Takahashi F; Sasaki S; Takahashi K
BMC Cancer; 2017 May; 17(1):302. PubMed ID: 28464801
[TBL] [Abstract][Full Text] [Related]
49. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.
Kennedy B; Branagan P; Moloney F; Haroon M; O'Connell OJ; O'Connor TM; O'Regan K; Harney S; Henry MT
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):228-36. PubMed ID: 26422568
[TBL] [Abstract][Full Text] [Related]
50. Early detection of colon cancer by increased serum level of Krebs von den Lungen-6 in a patient with dermatomyositis-associated interstitial pneumonia.
Fukuhara N; Tanino Y; Sato S; Fukuhara A; Uematsu M; Nikaido T; Misa K; Sato Y; Saito J; Wang X; Munakata M
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):265-70. PubMed ID: 26422573
[TBL] [Abstract][Full Text] [Related]
51. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome.
Remuzgo-Martínez S; Atienza-Mateo B; Ocejo-Vinyals JG; Genre F; Pulito-Cueto V; Mora-Cuesta VM; Iturbe-Fernández D; Lera-Gómez L; Pérez-Fernández R; Prieto-Peña D; Irure J; Romero-Bueno F; Sanchez-Pernaute O; Alonso-Moralejo R; Nuño L; Bonilla G; Vicente-Rabaneda EF; Grafia I; Prieto-González S; Narvaez J; Trallero-Araguas E; Selva-O'Callaghan A; ; ; Gualillo O; Cavagna L; Cifrián JM; Renzoni EA; Castañeda S; López-Mejías R; González-Gay MA
Sci Rep; 2021 Nov; 11(1):22574. PubMed ID: 34799647
[TBL] [Abstract][Full Text] [Related]
52. Prognostic value of serum Krebs von den Lungen-6 (KL-6) levels in COVID-19 pneumonia.
Letellier A; Rolland-Debord C; Luque-Paz D; Milon A; Choinier P; Blin E; Halitim P; Bravais J; Lefèvre G; Parrot A; Piéroni L; Cadranel J
Respir Med Res; 2023 Nov; 84():101054. PubMed ID: 37897878
[TBL] [Abstract][Full Text] [Related]
53. [Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].
Sun D; Cheng Z; Jiang TC; Li PF; Jia LQ; Wang TT; Zheng CP; Li Y; Duo MJ
Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(10):748-752. PubMed ID: 32192286
[No Abstract] [Full Text] [Related]
54. The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases.
Wang Y; Chen S; Zheng S; Lin J; Hu S; Zhuang J; Lin Q; Xie X; Zheng K; Zhang W; Du G; Zhang G; Hoffmann-Vold AM; Matucci-Cerinic M; Furst DE
Arthritis Res Ther; 2021 Aug; 23(1):212. PubMed ID: 34391465
[TBL] [Abstract][Full Text] [Related]
55. Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases.
Bergantini L; d'Alessandro M; Vietri L; Rana GD; Cameli P; Acerra S; Sestini P; Bargagli E
Immunol Res; 2020 Dec; 68(6):414-421. PubMed ID: 33089426
[TBL] [Abstract][Full Text] [Related]
56. 18F-FDG Uptake in Less Affected Lung Field Provides Prognostic Stratification in Patients with Interstitial Lung Disease.
Nobashi T; Kubo T; Nakamoto Y; Handa T; Koyasu S; Ishimori T; Mishima M; Togashi K
J Nucl Med; 2016 Dec; 57(12):1899-1904. PubMed ID: 27339874
[TBL] [Abstract][Full Text] [Related]
57. Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease.
Watanabe S; Kase K; Saeki K; Ohkura N; Murata A; Waseda Y; Takato H; Ichikawa Y; Yasui M; Kasahara K
Respir Med; 2022 Jan; 191():106689. PubMed ID: 34844174
[TBL] [Abstract][Full Text] [Related]
58. Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features.
Wang J; Zheng P; Huang Z; Huang H; Xue M; Liao C; Sun B; Zhong N
BMC Pulm Med; 2020 Dec; 20(1):315. PubMed ID: 33267857
[TBL] [Abstract][Full Text] [Related]
59. Serum KL-6, CA19-9, CA125 and CEA are Diagnostic Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Chinese Population.
Zheng M; Lou A; Zhang H; Zhu S; Yang M; Lai W
Rheumatol Ther; 2021 Mar; 8(1):517-527. PubMed ID: 33586127
[TBL] [Abstract][Full Text] [Related]
60. The Value of Biomarkers as Predictors of Outcome in Patients with Rheumatoid Arthritis-Associated Usual Interstitial Pneumonia.
Lee YS; Kim HC; Lee BY; Lee CK; Kim MY; Jang SJ; Lee HS; Moon J; Colby TV; Kim DS
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Oct; 33(3):216-223. PubMed ID: 27758986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
